文献速递免疫规划

带状疱疹活疫苗与四价流感病毒疫苗联合接种的免疫原性和安全性

Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
PubMed 文献 · Vaccine · 2017-08-19

一项随机、盲法、安慰剂对照试验纳入≥50岁成人,评估带状疱疹活疫苗(ZV)与四价灭活流感疫苗(IIV4)同时接种的免疫原性和安全性。440例入同时接种组、442例入序贯组;调整后VZV抗体GMT比值(同时组/序贯组)为0.87(95%CI 0.80, 0.95),达到预设非劣效标准;两组疫苗相关注射部位和全身不良事件频率相当,未观察到疫苗相关严重不良事件。

要点

  • ≥50岁成人同时接种ZV与IIV4,VZV抗体应答达到预设非劣效标准。
  • 同时组VZV抗体GMFR为1.9(95%CI 1.76, 2.05),达到可接受标准。
  • 两组疫苗相关注射部位和全身不良事件频率相当,无疫苗相关严重不良事件。

核心结论

  • ≥50岁成人同时接种ZV与IIV4诱导的VZV特异性和流感特异性抗体应答与单独接种任一种疫苗相当,且总体耐受性良好。

研究设计与样本

  • 随机、盲法、安慰剂对照试验(NCT02519855),纳入≥50岁成人,440例入同时接种组(CG)、442例入序贯组(SG)。
  • CG于第1天在不同注射部位接种ZV和IIV4,第4周接种匹配安慰剂;SG于第1天在不同注射部位接种安慰剂和IIV4(2015-2016流感季),第4周接种ZV。

主要发现

  • 调整后VZV抗体GMT比值(CG/SG)为0.87(95%CI 0.80, 0.95),达到预设非劣效标准。
  • CG的VZV抗体GMFR为1.9(95%CI 1.76, 2.05),达到可接受标准。
  • 流感抗体GMT比值:A/H1N1为1.02(95%CI 0.88, 1.18),A/H3N2为1.10(95%CI 0.94, 1.29),B/Yamagata为1.00(95%CI 0.88, 1.14),B/Victoria为0.99(95%CI 0.87, 1.13)。
  • 两组疫苗相关注射部位和全身不良事件频率相当;未观察到疫苗相关严重不良事件。

关键数值与推荐

  • VZV抗体采用糖蛋白酶联免疫吸附试验(gpELISA)检测,并按年龄和接种前滴度调整。
  • 流感毒株特异性GMT采用血凝抑制(HAI)试验检测。
  • 安全性终点包括任何疫苗接种后28天内的注射部位和全身不良事件,以及整个研究期间的严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Randomized, blinded, placebo-controlled trial to evaluate the safety and immunogenicity of ZOSTAVAX™ (ZV) administered concomitantly with quadrivalent inactivated influenza vaccine (IIV4) in adults≥50years of age (NCT02519855). METHODS: Overall, 440 participants were randomized into the Concomitant Group (CG) and 442 into the Sequential Group (SG). The CG received ZV and IIV4 at separate injection sites on Day 1 and matching placebo at Week 4. The SG received placebo and IIV4 (2015-2016 influenza season) at separate injection sites on Day 1 and ZV at Week 4. IMMUNOGENICITY ENDPOINTS: Varicella-zoster virus (VZV) antibody geometric mean titer (GMT) and geometric mean fold-rise (GMFR) from baseline to 4weeks postvaccination, measured by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and adjusted for age and prevaccination titer. Influenza strain-specific GMT at baseline and 4weeks postvaccination was measured by hemagglutination inhibition (HAI) assay. SAFETY ENDPOINTS: Injection-site and systemic adverse experiences (AEs) within 28days following any vaccination and serious AEs throughout the study. RESULTS: The adjusted VZV antibody GMT ratio (CG/SG) was 0.87 (95%CI: 0.80, 0.95), meeting the prespecified noninferiority criterion. The VZV antibody GMFR in the CG was 1.9 (95%CI: 1.76, 2.05), meeting the acceptability criterion. Influenza antibody GMT ratios for A/H1N1, A/H3N2, B/Yamagata and B/Victoria were 1.02 (95%CI: 0.88, 1.18), 1.10 (95%CI: 0.94, 1.29), 1.00 (95%CI: 0.88, 1.14), and 0.99 (95%CI: 0.87, 1.13), respectively. The frequency of vaccine-related injection-site and systemic AEs was comparable between groups. No vaccine-related serious AE was observed. CONCLUSION: The concomitant administration of ZV and IIV4 to adults≥50years of age induced VZV-specific and influenza-specific antibody responses that were comparable to those following administration of either vaccine alone, and was generally well tolerated.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Levin MJ, Buchwald UK, Gardner J, et al. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine. Vaccine. 2017. PMID: 28830693. doi:10.1016/j.vaccine.2017.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。